Published on
September 2, 2022

Psychedelic Weekly Headlines | September 2nd

Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.


Performance of psychedelic public companies this past week.

Company News

PharmAla Biotech ($MDMA) filed a patent application for 6 MDMA analogs and has been selected as the MDMA manufacturing partner for The University of Sydney's upcoming Phase II clinical trial. Details

Cybin ($CYBN) announced first patient dosing in their Phase I/IIa trial evaluating CYB003, a proprietary deuterated psilocybin analog, as a potential treatment for major depressive disorder. Press Release

Lobe Sciences ($LOBE | $LOBEF) entered into an investment agreement with Cantheon Capital to fund $1.5M USD toward clinical trials in Australia. Lobe Sciences will conduct three clinical trials evaluating their proprietary psilocin analogues. Press Release

Optimi Health ($OPTI | $OPTHF) entered into an international psilocybin supply agreement with Promises Innovative Recovery, a research and educational center focused on innovative treatments with psychedelic-assisted psychotherapy. Press Release

Filament Health ($FH | $FLHLF) began dosing patients with their natural psilocybin drug candidate in a Health Canada-approved clinical trial as part of ATMA Journey Centers' psychedelic-assisted therapist training program. Press Release

Mindset Pharma ($MSET | $MSSTF) identified three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds, further expanding their IP portfolio. Press Release

Core One Labs ($COOL | $CLABF) initiated rollout of their commercial sales strategy for their proprietary biosynthetic API psilocybin product. Press Release

Wesana Health ($WESA | $WSNAF) announced the sale of their clinic management assets for USD$2,100,000 as part of an effort to strengthen their balance sheet and streamline the company. Press Release

Mydecine Innovations ($MYCO | $MYCOF) signed a LOI to sell its wholly-owned subsidiary, Mindleap Health, to PanGenomic Health for a purchase price of C$4,000,000. Press Release


ARK Invest: How “Far Out” Are Psychedelic Therapeutics?

Forbes: Psychedelics And Mental Health: What Does The Science Say?

Psychology Today: Why Psychedelics May Be the Future of Health Care

VICE: The Trippy History of Magic Mushrooms

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.